Implanted capsule promises long-term relief from Type 1 diabetes
People suffering from Type 1 diabetes are set to benefit from an innovative therapy being developed in an EU-funded project that promises to restore the body's ability to regulate blood sugar via a small bioengineered implant.
© abidika #76848532, source: stock.adobe.com 2019
The EU-funded DRIVE project aims to provide a long-lasting solution to the therapeutic challenges of managing Type 1 Diabetes mellitus (T1D), a chronic condition characterised by high blood sugar that affects millions of people globally. If not controlled carefully usually through daily injections of blood-sugar regulating insulin the disease damages the eyes, kidneys and nerve endings, can cause heart disease and may lead to premature death.
The novel system being developed in DRIVE would eliminate the need for insulin injections.
Instead, a bioengineered capsule made of safe and natural materials, called a Î²-shell, would be implanted into the patients abdomen during a minimally invasive procedure. The capsule contains a gel, called Î²-gel, filled with pancreatic islet cells which, in healthy people, are responsible for secreting insulin from the pancreas to control blood sugar. These implanted Î²-cells would produce insulin inside T1D patients bodies, enabling them to live healthy and normal lives for up to five years before requiring a replacement implant.
DRIVEs Î²-System constitutes a significant advance on an existing but rarely used therapy for T1D diabetes involving the transplantation of pancreatic islet cells from donor pancreases, which offers patients natural blood-sugar control for only one or two years. The treatments high cost, the need for islet cells from several donor pancreases and the high risk of the patients body rejecting the transplanted cells means it is only currently offered to adults who have developed the severest complications from T1D.
Hitting the target
The DRIVE project addresses these challenges with the development of a completely new system to deliver pancreatic Î²-cells effectively in a smart and targeted way. This will mean fewer donor pancreases are needed for cell transplantation, allowing many more patients to avail of a more effective and longer-lasting treatment, says project manager Janice O'Sullivan at the Royal College of Surgeons in Ireland.
To obtain Î²-cells from donor pancreases, the DRIVE consortium has developed a process using bio-engineered enzymes optimised in laboratory trials, enabling the extraction of more purified Î²-cells from a single pancreas than current techniques. Added to the Î²-gel, which mimics a normal pancreatic environment, the cells are able to survive and continue to detect blood sugar and secrete insulin.
The encapsulating Î²-shell protects the cells from the bodys immune system, minimising the risk of rejection and reducing the patients need for long-term immunosuppressive medication.
Clinical trials and commercialisation
Pre-clinical testing has shown highly promising results, setting the stage for further development and human clinical trials in the near future. The DRIVE partners are designing optimised and scalable manufacturing processes in preparation for commercialisation of the Î²-System. The partners, who have applied for five patents for the technology, are also collaborating in a sister EU-funded project called DELIVER which will further develop advanced therapies with a focus on breaking insulin-dependency in children with Type 1 diabetes.
According to the World Health Organization, the direct healthcare costs of Type 1 and Type 2 diabetes, which together affect more than 382 million people worldwide, account for as much as 15 % of annual healthcare budgets. Direct costs exceed EUR 90 billion annually in five EU countries (France, Germany, Italy, Spain and the United Kingdom) alone, with a similar amount incurred in indirect costs such as work absenteeism, early retirement and social support.
Garry Duffy, the project coordinator at the National University of Ireland Galway, says the work conducted in DRIVE will have a significant impact on the social and economic burden of Type 1 diabetes.
DRIVEs innovative technologies will minimise the direct costs of diabetes and islet transplantation by optimising islet extraction from donor pancreases, cutting the number of islets required to regulate blood sugar effectively and reducing complications through increased surgical safety, localised immunoprotection and improved blood-sugar control.